Benefits, risks and costs of immunization for measles, mumps and rubella

For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3...

Full description

Saved in:
Bibliographic Details
Published in:American journal of public health (1971) 1985-07, Vol.75 (7), p.739-744
Main Authors: White, C C, Koplan, J P, Orenstein, W A
Format: Article
Language:English
Subjects:
Adolescent
Adult
Biological and medical sciences
Child
Child, Preschool
Cost-Benefit Analysis
Female
Humans
Immunization - economics
Male
Measles - complications
Measles - economics
Measles - prevention & control
Measles Vaccine
measles virus
Medical sciences
Mumps - complications
Mumps - economics
Mumps - prevention & control
Mumps Vaccine
mumps virus
Public health. Hygiene-occupational medicine
Risk
Rubella - complications
Rubella - economics
Rubella - prevention & control
Rubella Vaccine
rubella virus
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3,325,000 cases of measles would occur as compared to 2,872 actual cases in 1983 with a program. Instead of an expected 1.5 million rubella cases annually, there were only 3,816 actual cases. Mumps cases were lowered from an expected 2.1 million to 32,850 actual cases. Comparable reductions in disease-associated complications, sequelae, and deaths are gained with an immunization program. Without a vaccination program, disease costs would have been almost $1.4 billion. Based on the actual incidence of disease in 1983, costs were estimated to be approximately +14.5 million. Expenditures for immunization, including vaccine administration costs and the costs associated with vaccine reactions, totaled $96 million. The resulting benefit-cost ratio for the MMR immunization program is approximately 14:1. The savings realized due to the use of combination rather than single antigen vaccine total nearly $60 million.
ISSN:0090-0036
1541-0048
DOI:10.2105/AJPH.75.7.739